Trial Profile
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Biomarker; Pharmacodynamics
- 14 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 May 2025.
- 23 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 01 Nov 2023 Results assessing a secondary planned biomarker analysis of the TBCRC026 clinical trial dataset, published in the Journal of Nuclear Medicine.